AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+11.98%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$217M
AUM Growth
+$217M
(+19%)
Cap. Flow
+$29.3M
Cap. Flow
% of AUM
13.49%
Top 10 Holdings %
Top 10 Hldgs %
53.14%
Holding
73
New
14
Increased
11
Reduced
10
Closed
8
Top Buys
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$12.9M |
| 2 |
Sanofi
SNY
|
$11.4M |
| 3 |
Ventyx Biosciences
VTYX
|
$5.94M |
| 4 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
$5.57M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
$4.99M |
Top Sells
Sector Composition
| 1 | Healthcare | 84.3% |
| 2 | Financials | 1.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Establishment Labs
ESTA
$1.2B
| $17.8M | 4.98% | 326,668 -33,288 | -9% | -$1.82M |
|
|
KDNY
2
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $16M | 4.47% | 813,998 -123,570 | -13% | -$2.43M |
|
|
GBT
3
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $12.9M | 3.61% | +190,000 | New | +$12.9M |
|
|
4
Sanofi
SNY
$121B
| $11.4M | 3.18% | +300,000 | New | +$11.4M |
|
5
Ascendis Pharma
ASND
$11.8B
| $10.3M | 2.88% | 100,000 -25,087 | -20% | -$2.59M |
|
6
Kura Oncology
KURA
$686M
| $9.23M | 2.58% | 675,753 -252,503 | -27% | -$3.45M |
|
7
Lantheus
LNTH
$3.73B
| $9.14M | 2.55% | 130,000 -10,000 | -7% | -$703K |
|
|
NARI
8
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $8.72M | 2.43% | 120,000 -102,173 | -46% | -$7.42M |
|
9
AstraZeneca
AZN
$248B
| $8.23M | 2.3% | 150,000 +65,000 | +76% | +$3.56M |
|
10
Madrigal Pharmaceuticals
MDGL
$9.76B
| $6.5M | 1.81% | 100,000 | – | – |
|
|
11
Ventyx Biosciences
VTYX
$171M
| $5.94M | 1.66% | +170,000 | New | +$5.94M |
|
|
PNT
12
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $5.77M | 1.61% | 746,576 +720,998 | +2,819% | +$5.57M |
|
|
BLU
13
DELISTED
BELLUS Health Inc.
BLU
| $5M | 1.4% | 473,597 -19,681 | -4% | -$208K |
|
|
SWTX
14
DELISTED
SpringWorks Therapeutics
SWTX
| $4.99M | 1.39% | +175,000 | New | +$4.99M |
|
|
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
| $4.52M | 1.26% | 1,290,511 -81,733 | -6% | -$286K |
|
16
Rocket Pharmaceuticals
RCKT
$354M
| $4.27M | 1.19% | 267,794 +17,328 | +7% | +$277K |
|
|
MORF
17
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $4.15M | 1.16% | 146,491 -69,232 | -32% | -$1.96M |
|
18
Arcellx
ACLX
$3.85B
| $3.94M | 1.1% | 210,138 +135,138 | +180% | +$2.54M |
|
19
Zentalis Pharmaceuticals
ZNTL
$122M
| $3.68M | 1.03% | 170,000 +100,000 | +143% | +$2.17M |
|
20
Astria Therapeutics
ATXS
$349M
| $3.62M | 1.01% | +400,043 | New | +$3.62M |
|
|
VRNA
21
Verona Pharma
VRNA
$9.16B
| $3.58M | 1% | +350,000 | New | +$3.58M |
|
|
ARYE
22
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
| $3.47M | 0.97% | 352,500 | – | – |
|
23
Cytokinetics
CYTK
$4.23B
| $3.15M | 0.88% | 65,000 +50,000 | +333% | +$2.42M |
|
24
Cogent Biosciences
COGT
$1.69B
| $2.3M | 0.64% | 154,087 +29,087 | +23% | +$434K |
|
25
Celldex Therapeutics
CLDX
$1.47B
| $2.25M | 0.63% | 80,000 +40,000 | +100% | +$1.12M |
|